Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Calliditas Therapeutics Ab ADR (NQ: CALT )

40.00 UNCHANGED
Last Price Updated: 3:53 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 40.00
Bid (Size) 20.29 (2)
Ask (Size) 60.85 (2)
Prev. Close 40.00
Today's Range 40.00 - 40.00
52wk Range 16.00 - 42.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
The company previously had an accelerated approval for its IgA nephropathy treatment. 
Via Investor's Business Daily
CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Beats Revenue for Q2 2024
CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+60.01%
+60.01%
1 Month
N/A
N/A
3 Month
+1.73%
+1.73%
6 Month
+80.26%
+80.26%
1 Year
+133.10%
+133.10%

More News

Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY, MRO, SHCR, CALT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
Crude Oil Rises Sharply; Elbit Systems Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Asahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth Strategy
Via Benzinga
Dow Dips Over 100 Points; GameStop Shares Spike higher
Via Benzinga
Topics Stocks
Exposures US Equities
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why GameStop Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Apple To Rally Over 47%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Vera Therapeutics Stock Today?
Via Benzinga
Exposures Product Safety
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Intellectual Property Lawsuit Stocks
Exposures Financial Intellectual Property Legal
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.